300622 Doctorglasses Chain
- 15.53
- +0.04+0.26%
Doctorglasses Chain News
Dr. Glasses (300622) Update Report: High base is under pressure and expectations for steady improvement
Introduction to this report: Due to the impact of the high base in Q1 last year, net revenue and profit declined; with changes in the organizational system, online and offline joint development, and the increase in the share of functional lenses, we are optimistic about the steady recovery of the company's core business. Key points of investment: Maintaining an increase in holdings.
Dr. Glasses (300622): High base, short-term pressure to promote franchise+increase e-commerce, wait for an inflection point
Key investment income was -4%, and net profit to mother was -33%. 23Q1 was a high base. Excluding Douyin, income remained stable at 24Q1 at -4%, and net profit to mother was -33% year-on-year. Under the high base, performance was under pressure in the short term. 24Q
Minsheng Securities released a research report on April 27 stating that it gave Doctor Glasses (300622.SZ) a recommended rating. The main reasons for the rating include: 1) incident: Dr. Glasses released its 2024 quarterly report; 2) the year-on-year decl
Minsheng Securities released a research report on April 27 stating that it gave Doctor Glasses (300622.SZ) a recommended rating. The main reasons for the rating include: 1) incident: Dr. Glasses released its 2024 quarterly report; 2) the year-on-year decline in the local lifestyle service business affected the company's revenue growth rate, expecting steady sales growth due to further business adjustments; 3) Continued refinement of the franchise model to enable the expansion of the sinking market. By the end of 24Q1, the Concrete Glasses Alliance platform had a total of 598 franchise store users who completed the franchise signing process; 4) The gross margin was relatively stable, and a slight increase in sales expenses affected profitability. (The Daily Sutra
Doctor Glasses (300622) Quarterly Report Review: Under a high base, performance is slightly pressured, and digital retail is progressing steadily
The company released its 2024 quarterly report: the company achieved revenue of 296 million yuan (-4.5% year over year), net profit of 25 million yuan (YoY -32.9%), net profit of 23 million yuan (year-on-year) after deducting net profit of not attributable to mother of 0.23 million yuan (year-on-year -35)
Dr. Glasses (300622): Due to weak consumption, passenger flow is under pressure, revenue is stable, but net profit has declined a lot
Dr. Glasses revealed its quarterly report: In Q1, the company achieved revenue of 296 million yuan/-4.47% year over year, with a return of 25 million yuan/-32.85% year over year, after deducting not 23 million yuan/year on year -35.07%.
Dr. Glasses (300622.SZ): Net profit of 2,535,500 yuan in the first quarter decreased by 32.85% year on year
On April 25, Ge Longhui (300622.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 296 million yuan, down 4.47% year on year; net profit attributable to shareholders of listed companies was 25.355 million yuan, down 32.85% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 22.9386 million yuan, down 35.07% year on year; basic earnings per share were 0.14 yuan.
Express News | Dr. Glasses: The company's retail eyewear scale accounts for about 1% of China's eyewear product market
Dr. Glasses (300622): Net profit to mother +69% Online, local lifestyle, shopping malls and medical stores are the three major growth points
Revenue from key investment points grew steadily. Net profit to mother increased by 69% in line with expectations, while profitability rose steadily, revenue increased 22% in 23 years, and net profit to mother increased 69% in line with expectations. Revenue of 1.18 billion yuan in '23, up 22% from the same period, returned to mother
Dr. Glasses (300622): 69% increase in performance, product and architecture optimization enabled development
Introduction to this report: 2023 performance increased 69%. We are optimistic that the company will continue to empower future development by optimizing products and organizational structures, and that the performance expectations of single-store stores will continue to improve. Key points of investment: Maintaining an increase in holdings. 2023 Revenue 11.7
Dr. Glasses (300622): Direct store efficiency improved steadily in '23, channel deployment is expected to accelerate in '24
The company publishes its 2023 annual report. In 2023, the company achieved operating income of 1,176 billion yuan, a year-on-year increase of 22.2%, and net profit to mother of 128 million yuan, an increase of 68.9% over the previous year. The company completed the operation in a single Q4
Dr. Glasses (300622) 2023 Annual Report Review: 23-year performance is in line with expectations, the private brand and functional lens business have increased, and the omnichannel layout continues to deepen
Event: Dr. Glasses releases its 2023 annual report. In '23, the company achieved revenue of 1,176 billion yuan, yoy +22.20%; net profit to mother of 128 million yuan, yoy +68.93%; net profit not attributable to mother1
Dr. Glasses (300622) Annual Report Review Report: Digitalization Empowers Long-term Development Product Channel Structure Optimization
The company released its 2023 annual report: in 2023, it achieved revenue of 1,176 million yuan (+22.2% YoY), net profit to mother of 128 million yuan (+68.9% YoY); achieved revenue of 270 million yuan in Q4
Dr. Glasses (300622.SZ): Net profit for 2023 increased 68.93% to 128 million yuan, and plans to pay 10 to 6 yuan
On April 2, Ge Longhui (300622.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,176 billion yuan, an increase of 22.20%; net profit attributable to shareholders of listed companies was 128 million yuan, an increase of 68.93% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 116 million yuan, an increase of 82.90% year on year; basic income per share was 0.7400 yuan; it plans to distribute a cash dividend of 6 yuan (tax included) for every 10 shares to all shareholders.
Express News | Doctor glasses: The company has not developed military eye protection equipment
Dr. Glasses (300622) Company Review: Direct management is steady, and digital franchise is progressing steadily
The company announced its 2023 performance forecast. Net profit attributable to mother in 2023 was RMB 1.15-145 million (YoY +53.0%-92.9%), after deducting non-net profit of RMB 108-138 million (YoY +71.
Dr. Glasses (300622): Direct stores improve store efficiency, promote digital franchising, and promote impressive profit growth in 23 years
The company announced its 2023 performance forecast. The company expects to achieve net profit of 115 to 145 million yuan in 2023, an increase of 53.00%-92.92% over the previous year, and is expected to achieve net profit after deducting non-recurring profit and loss
Dr. Glasses (300622.SZ): 2023 net profit pre-increased by 53.00%-92.92%
On January 22, Ge Longhui (300622.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 115.0 million yuan to 145.0 million yuan, an increase of 53.00%-92.92% over the same period of the previous year; net profit profit after deducting non-recurring profit and loss was 10,800,000 yuan to 138.0 million yuan, an increase of 71.37% -118.97% over the same period last year. The main reasons why the company expects net profit attributable to shareholders of listed companies to increase in 2023 compared to the same period last year are: (1
Doctor Glasses (300622): Demand from smart glasses and eyewear service providers is growing
PhD research: Deeply involved in the smart glasses and co-founded the AR glasses brand MYVU with Meizu. On November 30, 23, Seiji Meizu released the AR smart glasses brand MYVU. Dr. Glasses was its eyewear service provider.
Doctor glasses (300622.SZ): Currently on sale in product categories suitable for people with silver hair, such as reading glasses as glasses and progressive multifocal lenses for adults
On January 8, Ge Longhui | Dr. Glasses (300622.SZ) said on an interactive platform that as China's population structure deepens further and the consumption capacity and demand for old-age services among middle-aged and elderly people gradually increases, the “silver hair economy” of the eyewear industry is becoming more and more prosperous. The company currently sells product categories suitable for people with silver hair, such as reading glasses as lenses and progressive multifocal lenses for adults. For specific sales performance and financial data, please refer to the company's subsequent regular reports and related announcements.
Dr. Glasses (300622.SZ): In 2024, the company will still maintain a relatively cautious store opening strategy
On January 5, Ge Longhui | Dr. Glasses (300622.SZ) said during a survey of specific subjects that the company will still maintain a relatively cautious store opening strategy in 2024, and will dynamically adjust the store opening plan in the future according to changes in the market environment. The company will continue to reach channel strategic alliances with high-quality supermarket partners, explore potential opportunities to develop new stores, and promote the quality and efficiency of old stores.
Analysis
Price Target
No Data
